Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin
نویسندگان
چکیده
منابع مشابه
Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin.
BACKGROUND Thrombocytopenia is a common hematologic disorder observed in patients with chronic hepatitis C virus (HCV) infection. Combined peginterferon (PEG-INF) and ribavirin treatment may exacerbate thrombocytopenia in patients with HCV. OBJECTIVE The aim of this pilot clinical trial was to assess the efficacy, tolerability and safety of Danazol in thrombocytopenia associated with PEG-INF ...
متن کاملRibavirin plasma concentration predicts sustained virological response to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients.
To the Editor: Despite the clinical benefits achieved with the use of antiretroviral agents, HIV-infected patients still suffer from high levels of psychological stress related to multiple inherent disease factors such as HIV nondisclosure, the presence of adverse events, or the fear of physical impairment. Many animal and human studies have demonstrated that stress accelerates HIV-1 disease pa...
متن کاملInterferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin.
A combination of nitazoxanide (NTZ), peginterferon (PegIFN), and ribavirin (RBV) may result in higher sustained virologic response (SVR) rates in hepatitis C virus (HCV) monoinfected patients. This study evaluated the effect of NTZ on interferon-stimulated gene (ISG) expression in vitro and in vivo among HIV/HCV genotype-1 (GT-1) treatment-naive patients. The ability of NTZ to enhance host resp...
متن کاملCharacteristics and outcomes of HCV genotype-1-infected patients treated with peginterferon and ribavirin combination therapy with discordant HCV responses 4 and 12 weeks after starting therapy.
OBJECTIVE Some patients with chronic hepatitis C virus (HCV) infection fail to achieve complete early virologic response (EVR) despite a marked decrease in HCV RNA at 4 weeks. We investigated the characteristics and final treatment outcomes of this patient subpopulation. METHODS A total of 516 patients with HCV genotype 1 were enrolled. Background characteristics and final outcomes were compa...
متن کاملPolymorphism of IL-28B Gene (rs12979860) in HCV Genotype 1 Patients Treated by Pegylated Interferon and Ribavirin
Background: Nowadays, the immune response to hepatitis C (HCV) treatment has become a crucial issue mostly due to the interleukin 28B (IL-28B) polymorphism effects in chronic HCV patients. The aim of this study was to detect the polymorphism of IL-28B gene (rs12979860) in HCV genotype 1 patients treated with pegylated Interferon and Ribavirin. Methods...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Hepatology
سال: 2011
ISSN: 1665-2681
DOI: 10.1016/s1665-2681(19)31513-3